Roche Ally Hetero Drugs Beat Ranbaxy, Cipla To Win Oseltamivir Supply Contract From Indian Government
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Hetero Drugs has edged past bigger Indian rivals Ranbaxy and Cipla to bag the government tender floated for supplies of oseltamivir. Hetero received orders to supply nine million capsules of generic versions of Roche's anti-viral brand Tamiflu. The entire contract is believed to be worth $6 to $8 million